LeMaitre Vascular (NASDAQ:LMAT) Hits New 1-Year High – Time to Buy?

LeMaitre Vascular, Inc. (NASDAQ:LMAT)’s stock price hit a new 52-week high during trading on Thursday . The stock traded as high as $106.99 and last traded at $105.88, with a volume of 116408 shares traded. The stock had previously closed at $103.44.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on LMAT. Oppenheimer reaffirmed an “outperform” rating and issued a $93.00 price objective (up from $90.00) on shares of LeMaitre Vascular in a research note on Friday, November 1st. Lake Street Capital began coverage on shares of LeMaitre Vascular in a research report on Friday, August 2nd. They set a “buy” rating and a $105.00 target price for the company. Barrington Research boosted their price target on LeMaitre Vascular from $92.00 to $93.00 and gave the stock an “outperform” rating in a report on Friday, November 1st. JMP Securities increased their price objective on LeMaitre Vascular from $77.00 to $100.00 and gave the company a “market outperform” rating in a research note on Tuesday, August 20th. Finally, Cantor Fitzgerald assumed coverage on shares of LeMaitre Vascular in a research note on Tuesday, October 15th. They set a “neutral” rating and a $96.00 price objective on the stock. Two equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $94.57.

LeMaitre Vascular Stock Up 2.3 %

The company has a market cap of $2.38 billion, a PE ratio of 56.52, a P/E/G ratio of 2.54 and a beta of 0.89. The stock’s 50 day simple moving average is $93.13 and its two-hundred day simple moving average is $86.47.

LeMaitre Vascular (NASDAQ:LMAT) last issued its earnings results on Thursday, October 31st. The medical instruments supplier reported $0.49 earnings per share for the quarter, beating analysts’ consensus estimates of $0.44 by $0.05. The firm had revenue of $54.82 million for the quarter, compared to analysts’ expectations of $53.50 million. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The firm’s revenue for the quarter was up 15.6% compared to the same quarter last year. During the same quarter last year, the firm earned $0.33 earnings per share. Analysts forecast that LeMaitre Vascular, Inc. will post 1.94 EPS for the current year.

LeMaitre Vascular Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 5th. Investors of record on Thursday, November 21st will be given a dividend of $0.16 per share. This represents a $0.64 dividend on an annualized basis and a yield of 0.60%. The ex-dividend date of this dividend is Thursday, November 21st. LeMaitre Vascular’s dividend payout ratio (DPR) is presently 34.97%.

Insider Buying and Selling at LeMaitre Vascular

In other LeMaitre Vascular news, Director Bridget A. Ross sold 3,750 shares of the firm’s stock in a transaction dated Friday, November 15th. The stock was sold at an average price of $101.47, for a total value of $380,512.50. Following the transaction, the director now directly owns 2,278 shares of the company’s stock, valued at $231,148.66. This trade represents a 62.21 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 10.79% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On LeMaitre Vascular

Large investors have recently modified their holdings of the stock. Glenmede Trust Co. NA boosted its holdings in LeMaitre Vascular by 1.3% in the 3rd quarter. Glenmede Trust Co. NA now owns 10,512 shares of the medical instruments supplier’s stock worth $976,000 after acquiring an additional 136 shares during the period. Summit Global Investments grew its stake in LeMaitre Vascular by 2.4% during the 3rd quarter. Summit Global Investments now owns 6,192 shares of the medical instruments supplier’s stock valued at $575,000 after purchasing an additional 146 shares in the last quarter. Shaker Investments LLC OH increased its holdings in LeMaitre Vascular by 1.3% during the 2nd quarter. Shaker Investments LLC OH now owns 13,833 shares of the medical instruments supplier’s stock worth $1,138,000 after purchasing an additional 175 shares during the last quarter. NBC Securities Inc. raised its position in shares of LeMaitre Vascular by 73.2% in the 3rd quarter. NBC Securities Inc. now owns 433 shares of the medical instruments supplier’s stock valued at $40,000 after purchasing an additional 183 shares in the last quarter. Finally, GAMMA Investing LLC boosted its stake in shares of LeMaitre Vascular by 34.3% during the 3rd quarter. GAMMA Investing LLC now owns 736 shares of the medical instruments supplier’s stock valued at $68,000 after buying an additional 188 shares during the last quarter. Institutional investors and hedge funds own 84.64% of the company’s stock.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.